Fate Therapeutics: Q4 Earnings Snapshot

SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $56.4 million in its fourth quarter.

The San Diego-based company said it had a loss of 58 cents per share.

The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 86 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $44.4 million in the period, which also beat Street forecasts. Nine analysts surveyed by Zacks expected $19.7 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE